U.S. Stock Market Midday Update

CalciMedica fell 12.07%. Based on recent key news:

1. On June 29, CalciMedica director Fred A. Middleton reported the indirect purchase of 248,972 shares of common stock at a price of $0.8 per share. This transaction increased the reported group's indirect holdings to 1,063,272 shares. Despite this positive insider buying behavior, market confidence in the company's future is lacking, leading to a decline in stock price.

2. On June 28, the market expressed concerns about CalciMedica's financial health, especially after the company failed to meet expected profit targets. Investor skepticism regarding the company's profitability intensified selling pressure.

3. On June 27, the overall industry performance was weak, particularly in the biotechnology sector, which was affected by macroeconomic uncertainties, leading to depressed investor sentiment and further dragging down CalciMedica's stock price. The biotechnology sector has recently shown weak performance, with significant capital outflows.

Top Stocks by Trading Volume in the Industry

Eli Lilly fell 1.65%. Based on recent key news:

1. On June 30, Eli Lilly transferred the commercialization rights of its breast cancer drug Verzenio in China to Innovent Biologics to address competitive pressure from generic drugs and improve sales efficiency. This move reflects the company's strategic adjustment in the later stages of the product lifecycle, resulting in a decline in stock price. Source: Jinshi Data

2. On June 30, U.S. job vacancy data for May exceeded market expectations, with the number of vacancies rising to 7.594 million, despite weak hiring activity, indicating that the overall labor market remains cautious. This supports the Federal Reserve's interest rate hike policy and affects market sentiment. Source: Zhitong Finance

3. On June 30, international oil prices fell back to near pre-war levels due to a rebound in shipping volume through the Strait of Hormuz, with WTI down about 19% this month, indicating a gradual recovery in energy transportation, which affects market risk appetite. Source: Wall Street Insight

Johnson & Johnson fell 1.21%. Based on recent news:

1. On June 30, Johnson & Johnson's DePuy Synthes appointed Christina Zamarro as the new CFO, and the market is cautious about her leadership capabilities, leading to a decline in stock price.

2. On June 30, analysts pointed out that Johnson & Johnson failed to make it onto their recommended list of the top five AI stocks, impacting investor confidence and putting pressure on the stock price.

3. On June 30, optimistic expectations for the global pharmaceutical R&D outsourcing industry boosted other pharmaceutical stocks, but Johnson & Johnson failed to benefit, leading to a decline in stock price. There are clear signs of capital returning to the pharmaceutical R&D outsourcing industry.

Merck fell 0.70%, with increased trading volume. Based on recent key news:

1. On June 30, U.S. lawmakers launched a national security investigation into Merck's clinical trials in China, believing that these trials could enhance China's military capabilities, leading to a decline in market confidence in Merck

2. On June 29, Merck announced an agreement with the HIV Drug Access and Resistance Crisis Working Group to improve drug accessibility and care services for HIV carriers. Although this move has a positive impact, it failed to boost the stock price.

3. On June 30, Bank of America Global Research raised Merck's target stock price to $141. Despite analysts giving it a moderate buy rating, the market reaction was limited. The pharmaceutical industry faces regulatory risks, and there is a noticeable outflow of funds.

Stocks Ranked Among the Top in Market Capitalization in the Industry

AstraZeneca fell 1.59%. Based on recent key news:

1. On June 29, AstraZeneca's Datroway received EU approval for the treatment of metastatic triple-negative breast cancer patients who are unable to receive PD-1/PD-L1 therapy. This approval is based on the results of the Phase III trial TROPION-Breast02, which showed a median overall survival of 23.7 months compared to 18.7 months for chemotherapy. This positive result has boosted market confidence in AstraZeneca, leading to stock price fluctuations.

2. On June 29, AstraZeneca's investments and strategic layout in China attracted attention. The government work report for the first time included the biopharmaceutical industry as an "emerging pillar industry." AstraZeneca's trillion-yuan investment aligns with national strategy, promoting its further development in the Chinese market.

3. On June 30, there was a divergence in analyst ratings. Deutsche Bank maintained a sell rating with a target price of £115, while JP Morgan maintained a buy rating with a target price of £160. The divergence in analyst opinions has led to uncertainty regarding AstraZeneca's future performance. The pharmaceutical industry enjoys policy support, and there is a noticeable inflow of funds